[DOI] [PubMed] [Google Scholar] 29.Clerk LH, Vincent MA, Barrett EJ, Lankford MF, Lindner JR
Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
Integration Of Dual GLP-1/GIP Agonist To Enhance Weight-Loss Efficacy In Obesity Treatment Major companies in the GLP-1 receptor agonist market are focusing on the integration of dual GLP-1/GIP agonist therapies designed to deliver greater weight-loss efficacy and broader metabolic benefits compared to traditional single-pathway treatments
FDA-approved weight loss medications (semaglutide and tirzepatide) require either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia
Farah, L
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects